Wednesday, July 18, 2018
 
 
Company News: Page (1) of 1 - 06/25/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Digital Patient Management Solution Veta Health Announces Residency At JLABS @ NYC
Move Lends Rapidly-Expanding Startup Access to Industry-Leading Resources and Expertise
(June 25, 2018)

NEW YORK, June 25, 2018 /PRNewswire/ -- Veta Health, the digital health platform that paints a complete picture of a patient's care journey for both clinicians and patients, announces the company's relocation to the newly-opened Johnson & Johnson Innovation, JLABS @ NYC.

"The company is humbled and grateful to be joining JLABS @ NYC, as it will provide us with the invaluable tools and resources we need to continue to grow and expand our business," says Veta Health co-founder Tanvi Abbhi. "This growth will ultimately allow us to provide more individuals the opportunity to receive unified and transparent care from their network of health providers."

Veta Health will look to take full advantage of the residency, specifically working to expand industry partnerships and further build the Veta Health digital product offering.



"We're so pleased to have this incredible opportunity to work alongside some of the healthcare industry's most forward-thinking companies," adds Nora Zetsche, co-founder of Veta Health. "This will not only help in growing our NYC footprint, but allow us to tap into strategic endeavors that go far beyond the walls of the innovation lab."

Veta Health is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world.  As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.

For more information on Veta Health, please visit http://www.myvetahealth.com/.

About Veta Health
Veta Health is a digital technology platform that creates better healthcare experiences for patients and healthcare professionals. Veta Health's platform enables multiple care providers, patients, and care partners to contribute to a patient's care journey to deliver a simplified, coordinated, and responsive healthcare experience. Veta Health's solution leverages existing data sources as well as patient-generated data from wearable devices and other patient-reported outcomes to achieve timely treatment and increased understanding between provider and patient.   

The Veta Health solution features a robust clinician portal, intuitive and simple patient experiences and streamlined internal processes to improve care experience across multiple touchpoints and provide complete insight into a client's overall population health.

Press Contact
Christine Kelly
(305) 916-3040
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/digital-patient-management-solution-veta-health-announces-residency-at-jlabs--nyc-300671175.html

SOURCE Veta Health

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Science,Medical,Business,Science,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Robotics Prosthetics Market Exclusive Analysis by MRFR | Industry Growing with 9.5% CAGR up to 2027 | The Demand for Robotic Prosthetic is Found to be Increasing across the Globe
  • Implantable Medical Devices Market Predicted to be Worth US$ 49.8 Bn by 2024, Says TMR
  • Global Cosmetic Chemicals Industry
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally - QYResearch.com
  • Association of Community Cancer Centers and Advisory Board Launch 9th Annual Trends in Cancer Care Survey
  • Small Animal Imaging Market is Estimated to Grow at a Faster Pace With the Significant CAGR During the Forecast Period: Radiant Insights, Inc.
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines